Peanut Oral Immunotherapy
Peanut Allergy
Phase 2Active
Key Facts
About Camallergy
Camallergy is a UK-based, private biotech developing patient-centric oral immunotherapies for food allergies, with an initial priority on peanut allergy. The company's programs are built upon over a decade of clinical research and real-world treatment experience at the Cambridge Peanut Allergy Clinic, where its foundational protocol has been used to treat over 200 children. Camallergy is integrating a novel dosing device into its treatment regimens to enhance precision and usability as it advances its pipeline into formal clinical trials.
View full company profileTherapeutic Areas
Other Peanut Allergy Drugs
| Drug | Company | Phase |
|---|---|---|
| INP20 | InnoUp | Clinical |
| Food Allergy Program | Hal Allergy | Clinical Development |
| Peanut allergy program | Desentum | Unknown |
| INT301 (implied) | Intrommune Therapeutics | Pre-clinical |
| VLP Peanut (VLP-p) | Allergy Therapeutics | Phase II |